Gilead (NASDAQ: GILD) CFO sells shares under 10b5-1 plan

Rhea-AI Filing Summary

GILEAD SCIENCES, INC. (GILD) reported that its Chief Financial Officer, Andrew D. Dickinson, sold 3,000 shares of common stock on 2026-08-17 at $138.36 per share in an open-market or private transaction. After this sale, he directly holds 165,646 shares. The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Insider Trade Summary 10b5-1

Net Seller: 3,000 shares

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 3,000 shs ($415K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	3,000	$138.36	$415K

Holdings After Transaction: Common Stock — 165,646 shares (Direct)

Footnotes (1)

1. F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Key Figures

Shares sold: 3,000 shares Sale price per share: $138.36 per share Shares owned after transaction: 165,646 shares +1 more

4 metrics

Shares sold 3,000 shares Non-derivative sale of common stock on 2026-08-17

Sale price per share $138.36 per share Price for 3,000 GILD common shares sold by CFO

Shares owned after transaction 165,646 shares Direct holdings of CFO Andrew D. Dickinson following the sale

Rule 10b5-1 plan adoption date August 29, 2024 Plan under which the 2026-08-17 sale was executed

Key Terms

Form 4, Rule 10b5-1 trading plan, non-derivative

3 terms

Form 4 regulatory

"The transaction reported in this Form 4 is made pursuant"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Rule 10b5-1 trading plan regulatory

"made pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

non-derivative financial

"transaction_type": "non-derivative""

FAQ

What insider transaction did GILEAD SCIENCES, INC. (GILD) disclose for Andrew D. Dickinson?

GILEAD SCIENCES, INC. disclosed that CFO Andrew D. Dickinson sold 3,000 shares of common stock on 2026-08-17 at $138.36 per share, reported as an open-market or private sale transaction.

How many GILD shares does the CFO hold after the reported Form 4 sale?

After the reported transaction, CFO Andrew D. Dickinson directly holds 165,646 GILD shares. This figure reflects his post-transaction ownership following the sale of 3,000 shares disclosed in the Form 4.

Was the GILD CFO’s 3,000-share sale made under a Rule 10b5-1 plan?

Yes. The sale of 3,000 GILD shares by CFO Andrew D. Dickinson was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024, indicating it was pre-arranged under that plan.

What was the price for the GILD shares sold by the CFO on 2026-08-17?

The 3,000 GILD shares sold by CFO Andrew D. Dickinson on 2026-08-17 were transacted at a price of $138.36 per share, according to the Form 4 non-derivative transaction details.

How many GILD shares in total did the CFO sell in this Form 4 filing?

In this Form 4 filing, CFO Andrew D. Dickinson reported the sale of 3,000 shares of GILEAD SCIENCES, INC. common stock. The transaction is categorized as a non-derivative sale in an open-market or private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/18/2026 - 07:06 PM Accepted by SEC EDGAR 08/18/2026 - 07:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CALIFORNIA 94404

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S(1)		3,000	D	$138.36	165,646	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)